CDK1 stabilizes HIF-1α via direct phosphorylation of Ser668 to promote tumor growth

Cell Cycle

Volumn 12, Issue 23, 2013, Pages 3689-3701

  Warfel, Noel A ^a   Dolloff, Nathan G ^a   Dicker, David T ^a   Malysz, Jozef ^a   El Deiry, Wafik S ^a  

^a PENN STATE CANCER INSTITUTE   (United States)

Author keywords

Angiogenesis; CDK1; Cell cycle; HIF 1 ; Hypoxia

Indexed keywords

ALSTERPAULLONE; ANTINEOPLASTIC AGENT; BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; CYCLIN B; CYCLIN B1; CYCLIN DEPENDENT KINASE 1; CYCLIN DEPENDENT KINASE 4; FLAVOPIRIDOL; HYPOXIA INDUCIBLE FACTOR 1ALPHA; PALBOCICLIB; PURVALANOL A; RO 3306; ROSCOVITINE; SERINE; UNCLASSIFIED DRUG;

ANGIOGENESIS; ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CANCER CHEMOTHERAPY; CANCER GROWTH; CELL CYCLE ARREST; CELL CYCLE PROGRESSION; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; FEMALE; G2 PHASE CELL CYCLE CHECKPOINT; GENE EXPRESSION REGULATION; GENE SILENCING; GENETIC TRANSCRIPTION; HALF LIFE TIME; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN STABILITY; SEQUENCE ALIGNMENT; STEADY STATE; TRANSCRIPTION INITIATION; TUMOR MICROENVIRONMENT; WESTERN BLOTTING; WILD TYPE;

ANGIOGENESIS; CDK1; CELL CYCLE; HIF-1Α; HYPOXIA;

ANIMALS; CDC2 PROTEIN KINASE; CELL HYPOXIA; CELL MOVEMENT; CELL PROLIFERATION; CYCLIN B1; CYCLIN-DEPENDENT KINASE 4; DOWN-REGULATION; ENZYME INHIBITORS; HCT116 CELLS; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; MICE; MICE, SCID; PHOSPHORYLATION; TUMOR SUPPRESSOR PROTEIN P53; UBIQUITINATION;

EID: 84890293880     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.26930     Document Type: Article

References (46)

1. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011; 144:646-74; PMID:21376230; http://dx.doi.org/10.1016/j.cell.2011.02.013
2. Semenza GL. HIF-1 and human disease: one highly involved factor. Genes Dev 2000; 14:1983-91; PMID:10950862
3. Semenza GL. Hypoxia-inducible factor 1 (HIF-1) pathway. Sci STKE 2007; 2007:cm8; PMID:17925579; http://dx.doi.org/10.1126/stke.4072007cm8
4. Harris AL. Hypoxia - a key regulatory factor in tumour growth. Nat Rev Cancer 2002; 2:38-47; PMID:11902584; http://dx.doi.org/10.1038/nrc704
5. Semenza GL. Hypoxia-inducible factor 1 and cancer pathogenesis. IUBMB Life 2008; 60:591-7; PMID:18506846; http://dx.doi.org/10.1002/iub.93
6. Wang GL, Jiang BH, Rue EA, Semenza GL. Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension. Proc Natl Acad Sci U S A 1995; 92:5510-4; PMID:7539918; http://dx.doi.org/10.1073/ pnas.92.12.5510
7. Semenza GL. Hydroxylation of HIF-1: oxygen sensing at the molecular level. Physiology (Bethesda) 2004; 19:176-82; PMID:15304631; http://dx.doi.org/10.1152/physiol.00001.2004
8. Bruick RK, McKnight SL. A conserved family of prolyl-4-hydroxylases that modify HIF. Science 2001; 294:1337-40; PMID:11598268; http://dx.doi.org/10.1126/ science.1066373
9. Ivan M, Kondo K, Yang H, Kim W, Valiando J, Ohh M, Salic A, Asara JM, Lane WS, Kaelin WG Jr. HIFalpha targeted for VHL-mediated destruction by proline hydroxylation: implications for O2 sensing. Science 2001; 292:464-8; PMID:11292862; http://dx.doi.org/10.1126/science.1059817
10. Maxwell PH, Wiesener MS, Chang GW, Clifford SC, Vaux EC, Cockman ME, Wykoff CC, Pugh CW, Maher ER, Ratcliffe PJ. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 1999; 399:271-5; PMID:10353251; http://dx.doi.org/10.1038/20459
11. Wenger RH, Stiehl DP, Camenisch G. Integration of oxygen signaling at the consensus HRE. Sci STKE 2005; 2005:re12; PMID:16234508
12. Rankin EB, Giaccia AJ. The role of hypoxia-inducible factors in tumorigenesis. Cell Death Differ 2008; 15:678-85; PMID:18259193; http://dx.doi.org/10.1038/cdd.2008.21
13. Baldewijns MM, van Vlodrop IJ, Vermeulen PB, Soetekouw PM, van Engeland M, de Bruïne AP. VHL and HIF signalling in renal cell carcinogenesis. J Pathol 2010; 221:125-38; PMID:20225241; http://dx.doi.org/10.1002/path.2689
14. Zhong H, Chiles K, Feldser D, Laughner E, Hanrahan C, Georgescu MM, Simons JW, Semenza GL. Modulation of hypoxia-inducible factor 1alpha expression by the epidermal growth factor/phosphatidylinositol 3-kinase/PTEN/AKT/FRAP pathway in human prostate cancer cells: implications for tumor angiogenesis and therapeutics. Cancer Res 2000; 60:1541-5; PMID:10749120
15. Richard DE, Berra E, Gothié E, Roux D, Pouysségur J. p42/p44 mitogen-activated protein kinases phosphorylate hypoxia-inducible factor 1alpha (HIF-1alpha) and enhance the transcriptional activity of HIF-1. J Biol Chem 1999; 274:32631-7; PMID:10551817; http://dx.doi.org/10.1074/jbc.274.46. 32631
16. Mylonis I, Chachami G, Samiotaki M, Panayotou G, Paraskeva E, Kalousi A, Georgatsou E, Bonanou S, Simos G. Identification of MAPK phosphorylation sites and their role in the localization and activity of hypoxia-inducible factor-1alpha. J Biol Chem 2006; 281:33095-106; PMID:16954218; http://dx.doi.org/10.1074/jbc.M605058200
17. Flügel D, Görlach A, Michiels C, Kietzmann T. Glycogen synthase kinase 3 phosphorylates hypoxia-inducible factor 1alpha and mediates its destabilization in a VHL-independent manner. Mol Cell Biol 2007; 27:3253-65; PMID:17325032; http://dx.doi.org/10.1128/MCB.00015-07
18. Isaacs JS, Jung YJ, Mimnaugh EG, Martinez A, Cuttitta F, Neckers LM. Hsp90 regulates a von Hippel Lindau-independent hypoxia-inducible factor-1 alpha-degradative pathway. J Biol Chem 2002; 277:29936-44; PMID:12052835; http://dx.doi.org/10.1074/jbc.M204733200
19. Xu D, Yao Y, Lu L, Costa M, Dai W. Plk3 functions as an essential component of the hypoxia regulatory pathway by direct phosphorylation of HIF-1alpha. J Biol Chem 2010; 285:38944-50; PMID:20889502; http://dx.doi.org/10. 1074/jbc.M110.160325
20. Kondo K, Klco J, Nakamura E, Lechpammer M, Kaelin WG Jr. Inhibition of HIF is necessary for tumor suppression by the von Hippel-Lindau protein. Cancer Cell 2002; 1:237-46; PMID:12086860; http://dx.doi.org/10.1016/S1535-6108(02) 00043-0
21. van den Heuvel S, Harlow E. Distinct roles for cyclin-dependent kinases in cell cycle control. Science 1993; 262:2050-4; PMID:8266103; http://dx.doi.org/10.1126/science.8266103
22. Hagting A, Jackman M, Simpson K, Pines J. Translocation of cyclin B1 to the nucleus at prophase requires a phosphorylation-dependent nuclear import signal. Curr Biol 1999; 9:680-9; PMID:10395539; http://dx.doi.org/10.1016/S0960- 9822(99)80308-X
23. Chen D, Gould C, Garza R, Gao T, Hampton RY, Newton AC. Amplitude control of protein kinase C by RINCK, a novel E3 ubiquitin ligase. J Biol Chem 2007; 282:33776-87; PMID:17893151; http://dx.doi.org/10.1074/jbc.M703320200
24. Hu CJ, Wang LY, Chodosh LA, Keith B, Simon MC. Differential roles of hypoxia-inducible factor 1alpha (HIF-1alpha) and HIF-2alpha in hypoxic gene regulation. Mol Cell Biol 2003; 23:9361-74; PMID:14645546; http://dx.doi.org/10. 1128/MCB.23.24.9361-9374.2003
25. Papandreou I, Cairns RA, Fontana L, Lim AL, Denko NC. HIF-1 mediates adaptation to hypoxia by actively downregulating mitochondrial oxygen consumption. Cell Metab 2006; 3:187-97; PMID:16517406; http://dx.doi.org/10. 1016/j.cmet.2006.01.012
26. Anastassiadis T, Deacon SW, Devarajan K, Ma H, Peterson JR. Comprehensive assay of kinase catalytic activity reveals features of kinase inhibitor selectivity. Nat Biotechnol 2011; 29:1039-45; PMID:22037377; http://dx.doi.org/10.1038/nbt.2017
27. Dolloff NG, Ma X, Dicker DT, Humphreys RC, Li LZ, El-Deiry WS. Spectral imaging-based methods for quantifying autophagy and apoptosis. Cancer Biol Ther 2011; 12:349-56; PMID:21757995; http://dx.doi.org/10.4161/cbt.12.4.17175
28. Mayes PA, Dolloff NG, Daniel CJ, Liu JJ, Hart LS, Kuribayashi K, Allen JE, Jee DI, Dorsey JF, Liu YY, et al. Overcoming hypoxia-induced apoptotic resistance through combinatorial inhibition of GSK-3β and CDK1. Cancer Res 2011; 71:5265-75; PMID:21646472; http://dx.doi.org/10.1158/0008-5472.CAN-11-1383
29. Vassilev LT, Tovar C, Chen S, Knezevic D, Zhao X, Sun H, Heimbrook DC, Chen L. Selective small-molecule inhibitor reveals critical mitotic functions of human CDK1. Proc Natl Acad Sci U S A 2006; 103:10660-5; PMID:16818887; http://dx.doi.org/10.1073/pnas.0600447103
30. Fry DW, Harvey PJ, Keller PR, Elliott WL, Meade M, Trachet E, Albassam M, Zheng X, Leopold WR, Pryer NK, et al. Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts. Mol Cancer Ther 2004; 3:1427-38; PMID:15542782
31. Shapiro GI. Cyclin-dependent kinase pathways as targets for cancer treatment. J Clin Oncol 2006; 24:1770-83; PMID:16603719; http://dx.doi.org/10. 1200/JCO.2005.03.7689
32. Ravi R, Mookerjee B, Bhujwalla ZM, Sutter CH, Artemov D, Zeng Q, Dillehay LE, Madan A, Semenza GL, Bedi A. Regulation of tumor angiogenesis by p53-induced degradation of hypoxia-inducible factor 1alpha. Genes Dev 2000; 14:34-44; PMID:10640274
33. Hornbeck PV, Kornhauser JM, Tkachev S, Zhang B, Skrzypek E, Murray B, Latham V, Sullivan M. PhosphoSitePlus: a comprehensive resource for investigating the structure and function of experimentally determined post-translational modifications in man and mouse. Nucleic Acids Res 2012; 40(Database issue):D261-70; PMID:22135298; http://dx.doi.org/10.1093/nar/gkr1122
34. Krishnamachary B, Berg-Dixon S, Kelly B, Agani F, Feldser D, Ferreira G, Iyer N, LaRusch J, Pak B, Taghavi P, et al. Regulation of colon carcinoma cell invasion by hypoxia-inducible factor 1. Cancer Res 2003; 63:1138-43; PMID:12615733
35. Talks KL, Turley H, Gatter KC, Maxwell PH, Pugh CW, Ratcliffe PJ, Harris AL. The expression and distribution of the hypoxia-inducible factors HIF-1alpha and HIF-2alpha in normal human tissues, cancers, and tumor-associated macrophages. Am J Pathol 2000; 157:411-21; PMID:10934146; http://dx.doi.org/10. 1016/S0002-9440(10)64554-3
36. Gordan JD, Bertout JA, Hu CJ, Diehl JA, Simon MC. HIF-2alpha promotes hypoxic cell proliferation by enhancing c-myc transcriptional activity. Cancer Cell 2007; 11:335-47; PMID:17418410; http://dx.doi.org/10.1016/j.ccr.2007.02.006
37. Goda N, Ryan HE, Khadivi B, McNulty W, Rickert RC, Johnson RS. Hypoxia-inducible factor 1alpha is essential for cell cycle arrest during hypoxia. Mol Cell Biol 2003; 23:359-69; PMID:12482987; http://dx.doi.org/10. 1128/MCB.23.1.359-369.2003
38. Kim WY, Kaelin WG. Role of VHL gene mutation in human cancer. J Clin Oncol 2004; 22:4991-5004; PMID:15611513; http://dx.doi.org/10.1200/JCO.2004.05. 061
39. Yoshida T, Tanaka S, Mogi A, Shitara Y, Kuwano H. The clinical significance of Cyclin B1 and Wee1 expression in non-small-cell lung cancer. Ann Oncol 2004; 15:252-6; PMID:14760118; http://dx.doi.org/10.1093/annonc/mdh073
40. Nozoe T, Korenaga D, Kabashima A, Ohga T, Saeki H, Sugimachi K. Significance of cyclin B1 expression as an independent prognostic indicator of patients with squamous cell carcinoma of the esophagus. Clin Cancer Res 2002; 8:817-22; PMID:11895914
41. Wang A, Yoshimi N, Ino N, Tanaka T, Mori H. WAF1 expression and p53 mutations in human colorectal cancers. J Cancer Res Clin Oncol 1997; 123:118-23; PMID:9030251; http://dx.doi.org/10.1007/BF01269890
42. Aaltonen K, Amini RM, Heikkilä P, Aittomäki K, Tamminen A, Nevanlinna H, Blomqvist C. High cyclin B1 expression is associated with poor survival in breast cancer. Br J Cancer 2009; 100:1055-60; PMID:19293801; http://dx.doi.org/10.1038/sj.bjc.6604874
43. Timofeev O, Cizmecioglu O, Settele F, Kempf T, Hoffmann I. Cdc25 phosphatases are required for timely assembly of CDK1-cyclin B at the G2/M transition. J Biol Chem 2010; 285:16978-90; PMID:20360007; http://dx.doi.org/10. 1074/jbc.M109.096552
44. Boutros R, Lobjois V, Ducommun B. CDC25 phosphatases in cancer cells: key players? Good targets? Nat Rev Cancer 2007; 7:495-507; PMID:17568790; http://dx.doi.org/10.1038/nrc2169
45. Moeller BJ, Dreher MR, Rabbani ZN, Schroeder T, Cao Y, Li CY, Dewhirst MW. Pleiotropic effects of HIF-1 blockade on tumor radiosensitivity. Cancer Cell 2005; 8:99-110; PMID:16098463; http://dx.doi.org/10.1016/j.ccr.2005.06.016
46. Wouters A, Pauwels B, Lardon F, Vermorken JB. Review: implications of in vitro research on the effect of radiotherapy and chemotherapy under hypoxic conditions. Oncologist 2007; 12:690-712; PMID:17602059; http://dx.doi.org/10. 1634/theoncologist.12-6-690